All Updates

All Updates

icon
Filter
Partnerships
Unilabs partners with C2N Diagnostics to expand Alzheimer's blood test access globally
Precision Medicine
Aug 7, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Partnerships
Alex Therapeutics partners with Navamedic to develop Parkinson's disease companion app
Preventive Healthcare
Yesterday
Funding
INFINIT raises USD 6 million in funding to enhance infrastructure
Decentralized Finance (DeFi)
Yesterday
Product updates
Salesforce announces suite of AI-powered autonomous agent solutions
Workflow Automation Platforms
Yesterday
FDA approval
FDA approves Apple AirPods Pro as over-the-counter hearing aids
Age Tech
Yesterday
Partnerships
Paradigm Health and Sheba Medical partner to optimize clinical trials
Clinical Trial Technology
Yesterday
Funding
XP Health raises USD 33.2 million in Series B funding to expand vision care platform
Health Benefits Platforms
Yesterday
Product updates
Circle expands Web3 Services product suite to Arbitrum
Web3 Ecosystem
Yesterday
Precision Medicine

Precision Medicine

Aug 7, 2024

Unilabs partners with C2N Diagnostics to expand Alzheimer's blood test access globally

Partnerships

  • Unilabs has partnered with C2N Diagnostics, a developer of Alzheimer's diagnostic solutions, to expand access to C2N's Precivity blood tests.

  • The multi-year partnership will make C2N's Precivity portfolio of blood tests available exclusively in Europe, including Norway, Switzerland, and the UK, as well as in Peru, Saudi Arabia, and the UAE. The agreement will facilitate a technology transfer of C2N's Alzheimer's blood biomarkers to deliver a Unilabs testing network across Europe.

  • C2N's Precivity blood tests aid in detecting amyloid plaques and tau tangles in the brain, which are hallmarks of Alzheimer's disease. The tests are intended for patients 55 years and older with signs of mild cognitive impairment or dementia and are only available for order by qualified healthcare providers.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.